WO2005112977A3 - Compositions for treatment with glucagon-like peptide, and methods of making and using the same - Google Patents

Compositions for treatment with glucagon-like peptide, and methods of making and using the same Download PDF

Info

Publication number
WO2005112977A3
WO2005112977A3 PCT/US2005/014128 US2005014128W WO2005112977A3 WO 2005112977 A3 WO2005112977 A3 WO 2005112977A3 US 2005014128 W US2005014128 W US 2005014128W WO 2005112977 A3 WO2005112977 A3 WO 2005112977A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
glucagon
peptide
treatment
making
Prior art date
Application number
PCT/US2005/014128
Other languages
French (fr)
Other versions
WO2005112977A2 (en
Inventor
Elijah M Bolotin
Original Assignee
Pharmain Ltd
Elijah M Bolotin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmain Ltd, Elijah M Bolotin filed Critical Pharmain Ltd
Publication of WO2005112977A2 publication Critical patent/WO2005112977A2/en
Publication of WO2005112977A3 publication Critical patent/WO2005112977A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

In part, the present invention is directed to compositions comprising a carrier with a metal binding domain, a metal ion, and GLP-l.
PCT/US2005/014128 2004-04-23 2005-04-22 Compositions for treatment with glucagon-like peptide, and methods of making and using the same WO2005112977A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56471004P 2004-04-23 2004-04-23
US60/564,710 2004-04-23

Publications (2)

Publication Number Publication Date
WO2005112977A2 WO2005112977A2 (en) 2005-12-01
WO2005112977A3 true WO2005112977A3 (en) 2006-08-17

Family

ID=35428848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014128 WO2005112977A2 (en) 2004-04-23 2005-04-22 Compositions for treatment with glucagon-like peptide, and methods of making and using the same

Country Status (2)

Country Link
US (2) US20050260259A1 (en)
WO (1) WO2005112977A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
US7138105B2 (en) * 2002-02-27 2006-11-21 Pharmain Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US20060188469A1 (en) * 2003-10-14 2006-08-24 Medivas, Llc Vaccine delivery compositions and methods of use
US20070160622A1 (en) * 2005-12-07 2007-07-12 Medivas, Llc Method for assembling a polymer-biologic delivery composition
US20080160089A1 (en) * 2003-10-14 2008-07-03 Medivas, Llc Vaccine delivery compositions and methods of use
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2007035938A2 (en) 2005-09-22 2007-03-29 Medivas, Llc BIS-(α-AMINO)-DIOL-DIESTER-CONTAINING POLY(ESTER AMIDE) AND POLY(ESTER URETHANE) COMPOSITIONS AND METHODS OF USE
WO2007038246A2 (en) 2005-09-22 2007-04-05 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
EP3000480A1 (en) 2005-12-01 2016-03-30 ProNAi Therapeutics, Inc. Cancer therapies and pharmaceutical compositions used therein
ES2390286T3 (en) * 2005-12-16 2012-11-08 Nektar Therapeutics GLP-1 polymer conjugates
KR101529318B1 (en) * 2005-12-19 2015-06-16 파마인 코포레이션 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US9534189B2 (en) * 2006-05-24 2017-01-03 Nalco Company Hydraulic fluids and fire-resistant fluids comprising glycerin containing by-products
EP3421031A1 (en) 2006-08-09 2019-01-02 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
CN101715340A (en) 2007-04-23 2010-05-26 精达制药公司 The mixed suspension preparation of insulinotropic peptide and application thereof
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
JP2011519867A (en) * 2008-05-01 2011-07-14 ノッド ファーマシューティカルズ， インコーポレイテッド Therapeutic calcium phosphate particles and methods of making and using the same
AU2009289529B2 (en) * 2008-09-04 2015-05-28 Amylin Pharmaceuticals, Llc Sustained release formulations using non-aqueous carriers
IT1391546B1 (en) * 2008-09-05 2012-01-11 Univ Firenze COMPLEXES OF MANGANESE AND COBALT, THEIR PREPARATION AND USE
WO2010126833A1 (en) * 2009-04-27 2010-11-04 Jerini Ophthalmic Inc. Sustained release formulations of peptidomimetic drugs and uses thereof
WO2011012715A1 (en) * 2009-07-31 2011-02-03 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
SI2462246T1 (en) 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
JP2013513622A (en) 2009-12-14 2013-04-22 ユニバーシティ オブ マサチューセッツ Methods for inhibiting cataracts and presbyopia
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
CN103748139B (en) 2011-06-23 2016-08-17 帝斯曼知识产权资产管理有限公司 For delivering the micron particle comprising biodegradable polyester-amide copolymer or the nano-particle of bioactivator
US20150299803A1 (en) 2012-11-05 2015-10-22 Pronai Therapeutics, Inc. Methods of Using Biomarkers for the Treatment of Cancer by Modulation of BCL2 Expression
CN105209033B (en) 2013-03-14 2018-09-18 马萨诸塞大学 Inhibit cataract and presbyopic method
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN107106509B (en) 2014-12-18 2021-11-30 帝斯曼知识产权资产管理有限公司 Drug delivery system for delivering acid sensitive drugs
CN111388680B (en) * 2015-01-28 2024-01-05 中国科学院天津工业生物技术研究所 Application of polypeptide complex as polypeptide or protein drug carrier, method and fusion protein complex thereof
KR102650751B1 (en) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 Implant placement and removal systems
KR20180083378A (en) 2015-11-13 2018-07-20 유니버시티 오브 매사추세츠 Bifunctional molecules, including PEG for use in cataracts and presbyopia
SG10201913699QA (en) 2016-05-16 2020-03-30 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
CN109675020B (en) * 2019-01-11 2021-05-04 浙江大学 Oral GLP-1 polypeptide nano preparation and preparation method and application thereof
US20220306670A1 (en) 2019-06-18 2022-09-29 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Site-specific, kinetically inert conjugation of labels and/or carriers to target molecules such as his-tagged proteins via metal complex reagents
JP2022537042A (en) * 2019-06-21 2022-08-23 ウニベルシテ カソリーク デ ルーベン Lipid nanocapsules loaded with incretin mimetics
CN115887529A (en) * 2022-11-24 2023-04-04 江汉大学 Cinnamon flavone extract, preparation thereof and application thereof in diabetes drugs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050237A1 (en) * 1993-04-07 2003-03-13 Scios Inc. Prolonged delivery of peptides

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US6849708B1 (en) * 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US7138486B2 (en) * 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5527524A (en) * 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
US4857311A (en) * 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US5681543A (en) * 1988-02-29 1997-10-28 Shering Aktiengesellschaft Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
US5776894A (en) * 1988-12-05 1998-07-07 Novartis Ag Chelated somatostatin peptides and complexes thereof, pharmaceutical compositions containing them and their use in treating tumors
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
EP0610441A4 (en) * 1991-10-29 1996-01-10 Clover Cons Ltd Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release.
US5770563A (en) * 1991-12-06 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof
AU682308C (en) * 1992-04-03 2006-08-17 Regents Of The University Of California, The Self-assembling polynucleotide delivery system
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
EP0665729B1 (en) * 1992-09-04 2003-05-07 The General Hospital Corporation Biocompatible polymers containing diagnostic or therapeutic moieties
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5605672A (en) * 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
US5763585A (en) * 1993-10-13 1998-06-09 Anergen, Inc. Method of making MHC-peptide complexes using metal chelate affinity chromatography
PL181064B1 (en) * 1994-03-07 2001-05-31 Dendritech Inc Biologically active and/or oriented conjugates of dendrimers
WO1995024929A2 (en) * 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
US5466467A (en) * 1994-03-30 1995-11-14 The United States Of America As Represented By The Secretary Of The Navy Liposomes containing polymerized lipids for non-covalent immobilization of proteins and enzymes
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US20010006943A1 (en) * 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
US5834428A (en) * 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5929031A (en) * 1995-05-02 1999-07-27 Baxter Biotech Technology Sarl Storage stable hemoglobin solutions
US5855610A (en) * 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
US6521211B1 (en) * 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
WO1996041818A1 (en) * 1995-06-09 1996-12-27 Drohan William N Chitin hydrogels, methods of their production and use
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
EP0856026A1 (en) 1995-10-19 1998-08-05 Receptagen Corporation Discrete-length polyethylene glycols
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US7235627B2 (en) * 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (en) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
BR9811793A (en) * 1997-07-18 2000-09-26 Infimed Inc Biodegradable macromers for the controlled release of biologically active substances.
US6468532B1 (en) * 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6998387B1 (en) * 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
AU776514B2 (en) * 1998-08-10 2004-09-09 General Hospital Corporation, The Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof
DE69935435T2 (en) * 1998-08-12 2007-12-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ammonium sulfate gradient prepared liposomal analgesic compositions
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
CN1338924A (en) * 1999-01-08 2002-03-06 艾米斯菲尔技术有限公司 Polymeric delivery agents and delivery agent compounds
US6365173B1 (en) * 1999-01-14 2002-04-02 Efrat Biopolymers Ltd. Stereocomplex polymeric carriers for drug delivery
CA2328614C (en) * 1999-02-12 2012-06-26 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
CA2371011C (en) * 1999-04-28 2009-12-22 Eidgenossisch Technische Hochschule Zurich Polyionic coatings in analytic and sensor devices
US6569832B1 (en) * 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
CA2402733A1 (en) * 2000-03-14 2001-09-20 Burkhard Goke Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
CN1462191B (en) * 2000-05-19 2013-07-24 埃米林药品公司 Treatment of ocute coronary syndrome with GLP-1
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
US7807780B2 (en) 2000-07-21 2010-10-05 Revance Therapeutics, Inc. Multi-component biological transport systems
US20040092432A1 (en) * 2000-08-24 2004-05-13 Thomas Jefferson University Peptide compositions with effects on cerebral health
US6521736B2 (en) * 2000-09-15 2003-02-18 University Of Massachusetts Amphiphilic polymeric materials
WO2002034285A2 (en) * 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
US20020132254A1 (en) * 2000-11-30 2002-09-19 Twu Jesse J. Molecular labeling and assay systems using poly (amino acid)-metal ion complexes as linkers
WO2002048192A2 (en) * 2000-12-13 2002-06-20 Eli Lilly And Company Amidated glucagon-like peptide-1
EP2186824A3 (en) * 2000-12-13 2010-09-22 Eli Lilly & Company Chronic treatment regimen using glucagon-like insulinotropic peptides
ITMI20011057A1 (en) * 2001-05-22 2002-11-22 Bracco Imaging Spa PREPARATION AND USE OF CYCLIC AND RAMIFIED PEPTIDES AND THEIR DERIVATIVES MARKED AS THERAPEUTIC AGENTS AGONISTS OR ANTAGONISTS OF THE COLECISTOCHI
US7144863B2 (en) 2001-06-01 2006-12-05 Eli Lilly And Company GLP-1 formulations with protracted time action
ATE382057T1 (en) * 2001-06-28 2008-01-15 Novo Nordisk As STABLE FORMULATION OF MODIFIED GLP-1
US6586524B2 (en) * 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
CA2458371A1 (en) * 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
SK1432004A3 (en) * 2001-10-01 2005-03-04 Eli Lilly And Company Medicament for reducing mortality and morbidity associated with critical illnesses
US7041646B2 (en) * 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
KR20040058324A (en) * 2001-11-26 2004-07-03 다이이찌 산토리 파마 가부시키가이샤 Medicinal compositions for nasal absorption
CN1332711C (en) * 2002-02-20 2007-08-22 埃米球科技有限公司 Method for administering GLP-1 molecules
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7138105B2 (en) * 2002-02-27 2006-11-21 Pharmain Compositions for delivery of therapeutics and other materials, and methods of making and using the same
ES2327328T3 (en) * 2002-07-04 2009-10-28 Zealand Pharma A/S GLP-1 AND PROCEDURES FOR THE TREATMENT OF DIABETES.
US20040209803A1 (en) * 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
AU2004227837A1 (en) * 2003-03-31 2004-10-21 Alza Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
EP1631308B1 (en) * 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
ATE529126T1 (en) * 2003-06-03 2011-11-15 Novo Nordisk As STABILIZED PHARMACEUTICAL PEPTIDE COMPOSITIONS
EP2292254A3 (en) * 2003-06-03 2011-12-14 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
US20060247167A1 (en) * 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
AR047776A1 (en) * 2003-12-16 2006-02-22 Sod Conseils Rech Applic GLP PHARMACEUTICAL COMPOSITIONS - 1
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
AU2005251676B2 (en) * 2004-03-03 2011-09-29 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
FR2867679B1 (en) * 2004-03-17 2008-08-22 Oreal COSMETIC COMPOSITION COMPRISING MODIFIED POLYAMINES AND USES THEREOF.
DK1737899T3 (en) * 2004-04-20 2015-09-28 Dendritic Nanotechnologies Inc Dendritic POLYMERS WITH ENHANCED AMPLIFICATION AND HOME FUNCTIONALITY
US9089636B2 (en) * 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
EP1773878B1 (en) * 2004-07-19 2015-03-04 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US7285529B2 (en) * 2005-02-28 2007-10-23 Gene Tools, Llc Embedder compositions and methods for detecting and killing cells in acidic areas of tumors
KR101529318B1 (en) * 2005-12-19 2015-06-16 파마인 코포레이션 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050237A1 (en) * 1993-04-07 2003-03-13 Scios Inc. Prolonged delivery of peptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CALICETI P. ET AL: "Pharmacokinetic and Biodistribution Properties of Poly(ethylene glycol)-Protein Conjugates", ADVANCED DRUG DELIVERY REVIEWS, vol. 55, 2003, pages 1261 - 1277, XP003001867 *
TERPE K.: "Overview of Tag Protein Fusions: From Molecular and Biochemical Fundamentals to Commercial Systems", APPL. MICROBIOLOGY BIOTECHNOL., vol. 60, 2003, pages 523 - 533, XP002298417 *

Also Published As

Publication number Publication date
US7589169B2 (en) 2009-09-15
WO2005112977A2 (en) 2005-12-01
US20050260259A1 (en) 2005-11-24
US20060093660A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
WO2005112977A3 (en) Compositions for treatment with glucagon-like peptide, and methods of making and using the same
WO2006058237A3 (en) Polymer-coated substrates for binding biomolecules and methods of making and using thereof
WO2006122156A3 (en) Compounds for modulating trpv3 function
WO2007056124A3 (en) Compounds for modulating trpv3 function
WO2006033859A3 (en) Compositions and methods for protein production
EP1713440A4 (en) Engineered proteins, and methods of making and using
IL182765A0 (en) Pyridazine compounds, compositions and methods
WO2007073505A3 (en) Trpa1 inhibitors for treating pain
ZA200709266B (en) Human GLP-1 mimetibodies, compositions, methods and uses
WO2006017538A3 (en) Hk1-binding proteins
IL183940A0 (en) Glp-1 agonists, compositions, methods and uses
ZA200711243B (en) Vasoactive kit and composition and uses thereof
WO2006071960A3 (en) Compositions and methods of treating cell proliferation disorders
RS60616B1 (en) Human anti-il-23 antibodies, compositions, method and uses
WO2005117939A3 (en) Use of GPCR54 ligands for the treatment of infertility
IL191137A0 (en) Polycation-polyanion complexes, compositions and methods of use thereof
WO2006102061A3 (en) Methods of decreasing calcification
SG131099A1 (en) Polishing method, polishing composition and polishing composition kit
EP1974370A4 (en) Microetching composition and method of using the same
SG156664A1 (en) Metal ion-containing cmp composition and method for using the same
EP1733058B8 (en) Iron sucrose complexes and method of manufacture thereof
AU2006329879A8 (en) Compounds and methods for inhibiting the interaction of Bcl proteins with binding partners
IL184062A0 (en) Visco-supplement composition and methods
WO2006084153A3 (en) Methods and materials with trans-clomiphene for the treatment of male infertility
WO2006060079A3 (en) Methods and compositions for treating nephrogenic diabetes insipidus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase